tumor protein p53 binding protein 2Genealiases: 53BP2 · ASPP2 · BBP · P53BP2 · PPP1R13A
Q-omics provides the consensus-scored TP53BP2 profile across patient tissues and cancer cell-line models. TP53BP2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TP53BP2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TP53BP2 RNA expression shows 19,948 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TP53BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP53BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP53BP2 survival associations across molecular data types. TP53BP2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP53BP2 RNA expression–survival associations across cancer types. High TP53BP2 expression shows unfavorable associations in ACC, MESO, KICH, UCEC and SARC, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TP53BP2 RNA expression.
This table summarizes TP53BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TP53BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP53BP2 shows lower tumor expression in KICH and LUSC and higher tumor expression in HNSC, LIHC, KIRP and CHOL. The HNSC box plot shows higher TP53BP2 RNA expression in tumor versus normal tissue (log2 FC = +0.829, t-test p < 0.001).
This table shows molecular features associated with TP53BP2 in patient tissues and cancer cell lines. In patient samples, TP53BP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TP53BP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
